VR496 ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
299	嚢胞性線維症	4

299. 嚢胞性線維症

---

臨床試験数 : 1,696 /  薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2007-006276-11-IT (EUCTR)	18/05/2010	07/05/2010	A Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in patients with Cystic Fibrosis (CF) - ND	A Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in patients with Cystic Fibrosis (CF) - ND	Cystic Fibrosis MedDRA version: 9.1;Level: LLT;Classification code 10011763	Product Name: heparin 25mg inhalation powder, hard capsule Product Code: VR496	VECTURA LIMITED	NULL	Not Recruiting			Female: yes Male: yes	64	Phase 1/2	Ireland;Italy
2	EUCTR2007-006276-11-IE (EUCTR)	11/11/2008	11/02/2008	A Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in adults with Cystic Fibrosis (CF) - VR496/005- Orally inhaled heparin in adults with Cystic Fibrosis	A Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in adults with Cystic Fibrosis (CF) - VR496/005- Orally inhaled heparin in adults with Cystic Fibrosis	Cystic Fibrosis MedDRA version: 9.1;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lung	Product Name: Heparin 25mg inhalation powder, hard capsule INN or Proposed INN: HEPARIN SODIUM	Vectura Limited	NULL	Not Recruiting			Female: yes Male: yes	64	Phase 1/2	Ireland;Italy
3	EUCTR2007-006276-11-GB (EUCTR)	01/09/2008	26/11/2007	A Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in patients with Cystic Fibrosis (CF) - VR496/005- Orally inhaled heparin in patients with Cystic Fibrosis	A Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in patients with Cystic Fibrosis (CF) - VR496/005- Orally inhaled heparin in patients with Cystic Fibrosis	Cystic Fibrosis MedDRA version: 9.1;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lung	Product Name: Heparin 25mg inhalation powder, hard capsule INN or Proposed INN: HEPARIN SODIUM	Vectura Limited	NULL	Not Recruiting			Female: yes Male: yes	64	Phase 1/2	Ireland;Italy;United Kingdom
4	EUCTR2007-006276-11-PL (EUCTR)		06/05/2009	A Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in patients with Cystic Fibrosis (CF) - VR496/005- Orally inhaled heparin in patients with Cystic Fibrosis	A Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in patients with Cystic Fibrosis (CF) - VR496/005- Orally inhaled heparin in patients with Cystic Fibrosis	Cystic Fibrosis MedDRA version: 9.1;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lung	Product Name: Heparin 25mg inhalation powder, hard capsule INN or Proposed INN: HEPARIN SODIUM	Vectura Limited	NULL	Not Recruiting			Female: yes Male: yes	64	Phase 2	Poland;Ireland;Italy;United Kingdom